Hyper-CVAD Program in Burkitt's-Type Adult Acute Lymphoblastic Leukemia

摘要: PURPOSE: To evaluate response and outcome with a front-line intensive multiagent chemotherapy regimen in adults Burkitt's-type acute lymphoblastic leukemia (B-ALL). PATIENTS AND METHODS: From September 1992 to June 1997, 26 consecutive newly diagnosed untreated B-ALL received hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone (Hyper-CVAD). Their median age was 58 years (range, 17 79 years), 46% were ≥ 60 years. Patients Hyper-CVAD alternated courses of high-dose methotrexate cytarabine. Granulocyte colony-stimulating factor prophylactic antibiotics administered for all eight planned courses. CNS prophylaxis intrathecal cytarabine on days 2 7 each course. RESULTS: Complete remission (CR) obtained 21 patients (81%). There five induction deaths (19%). The time CR 22 15 89 days); 70% achieved within 4 weeks. 3-year survival rate 49% (± 11%); th...